scholarly journals Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement

2020 ◽  
Vol 10 (4) ◽  
pp. 524-541
Author(s):  
Shashank Chaturvedi ◽  
Anurag Verma ◽  
Vikas Anand Saharan
Keyword(s):  
Drug Exposure ◽  
Biological Membrane ◽  
Cancer Therapeutics ◽  
Drug Carriers ◽  
Cancer Drugs ◽  
Proliferating Cells ◽  
Bioavailability Enhancement ◽  
Glycoprotein P ◽  
Anti Cancer ◽  
Lymphatic Route

In the treatment of cancer, chemotherapy plays an important role though the efficacy of anticancer drug administered orally is limited, due to their poor solubility in physiological medium, inability to cross biological membrane, high Para-glycoprotein (P-gp) mediated drug efflux, and pre-systemic metabolism. These all factors cumulatively reduce drug exposure at the target site leading to multidrug resistance (MDR). Lipid based carriers systems has been explored to overcome solubility and permeability related issues of anti-cancer drugs. The lipid based formulations have also been reported to circumvent the effect of P-gp and CYP3A4. Further long chain triglycerides (LCT) has shown their ability to access Lymphatic route over Medium Chain Triglycerides, as the former has been extensively used for targeting anti-cancer drugs at proliferating cells through lymphatic route. Therefore this review tries to reflect the usefulness of lipid based drug carriers systems (viz. liposome, solid lipid nanoparticle, nano-lipid carriers, self-emulsifying, lipidic pro-drugs) in targeting lymphatic system and overcoming issues related to solubility and permeability of anti-cancer drugs. Moreover, we have also tried to reflect how critically lipid based carriers are important in maximizing therapeutic safety and efficacy of anti-cancer drugs.

Gold nanospheres and nanorods for anti-cancer therapy: comparative studies of fabrication, surface-decoration, and anti-cancer treatments

Nanoscale ◽  
2020 ◽  
Vol 12 (28) ◽  
pp. 14996-15020
Author(s):  
Wei Mao ◽  
Young Ju Son ◽  
Hyuk Sang Yoo
Keyword(s):  
Gold Nanoparticles ◽  
Cancer Therapy ◽  
Cancer Therapeutics ◽  
Drug Carriers ◽  
Gold Nanospheres ◽  
Cancer Treatments ◽  
Anti Cancer ◽  
Diagnostic Agents ◽  
Irradiation Therapy ◽  
Surface Decoration

Various gold nanoparticles have been explored as cancer therapeutics because they can be widely engineered for use as efficient drug carriers and diagnostic agents, and in photo-irradiation therapy.

Safe and Effective Kinase Inhibitors for the Treatment of Gynecological Cancers: In Silico Approach

2021 ◽  
Vol 22 ◽  
Author(s):  
Vaishali M. Patil ◽  
Abhishek Kumar ◽  
Vaishali Anand ◽  
Priya Bansal ◽  
Neeraj Masand
Keyword(s):  
Mortality Rate ◽  
Anticancer Agents ◽  
In Silico ◽  
Kinase Inhibitors ◽  
Developmental Toxicity ◽  
Reproductive Toxicity ◽  
Cancer Therapeutics ◽  
Cancer Drugs ◽  
Gynecological Cancers ◽  
Anti Cancer

Aims: To study various types of gynecological cancers and the available therapeutics to investigate safe and effective drugs. Background: Cancer is the most common cause of mortality throughout the world. When the statistics is considered for gynecological cancers, ovarian, cervical and uterine cancers are among the most prevalent types. They have worst prognosis and the highest mortality rate and by the year 2040 significant increase in mortality rate is predicted. Objective: The major limitation with development of anti-cancer therapeutics for the gynecological cancers are safety of the therapeutics for the developing fetus as well as the mother. Various medicinal classes of natural to synthetic therapeutics have been reported including kinase inhibitors as the most promising category of anti-cancer drugs. Method: A dataset of kinase inhibitory clinically approved anticancer agents was derived through literature review. A QSAR based approach i.e. VEGAQSAR has been applied to evaluate the reproductive and developmental toxicity for the selected class of kinase inhibitors. Result: In the present work, the promising category of anticancer kinase inhibitors has been investigated for its toxicity potential with the help of in silico approach. The anti-cancer kinase inhibitors were categorized based on the found non-toxic or toxic properties towards reproductive and developmental toxicity. Conclusion: Early prediction of the available or proposed anti-cancer therapeutics for their contribution towards developmental and reproductive toxicity is an important criterion for their use in pregnancy associated cancers. The investigation of toxicity profile of available anti-cancer kinase therapeutics will be helpful to design and develop novel and safe anti-cancer drugs in the near future. Other: The study outcomes will benefit the current anticancer drug development efforts.

Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes

2016 ◽  
Vol 4 (4) ◽  
pp. 627-638 ◽  
Author(s):  
Gopikrishna Moku ◽  
Suresh Kumar Gulla ◽  
Narendra Varma Nimmu ◽  
Sara Khalid ◽  
Arabinda Chaudhuri
Keyword(s):  
Drug Carriers ◽  
Ph Sensitive ◽  
Acidic Ph ◽  
Cancer Drugs ◽  
Tumor Tissues ◽  
Anti Cancer ◽  
Endosomal Ph

Numerous prior studies have been reported on the use of pH-sensitive drug carriers such as micelles, liposomes, peptides, polymers, nanoparticles,etc. that are sensitive to the acidic (pH = ∼6.5) microenvironments of tumor tissues.

scholarly journals Assessment of causality and severity of various reported adverse drug reactions by different classes of anti-cancer drugs

2018 ◽  
Vol 7 (3) ◽  
pp. 503
Author(s):  
Shaheena Rasool ◽  
Masarat Nazeer ◽  
Mehwish Majeed
Keyword(s):  
Adverse Drug Reactions ◽  
Radiation Oncology ◽  
Case Reports ◽  
Therapeutic Index ◽  
Severe Form ◽  
Antineoplastic Drugs ◽  
Cancer Drugs ◽  
Drug Reactions ◽  
Proliferating Cells ◽  
Anti Cancer

Background: Chemotherapy involves highly complex regimens and hence accounts to high susceptibility towards Adverse Drug Reactions. All antineoplastic drugs have potential to cause one or more Adverse Drug Reactions which may vary from mild to severe form. So the aim of this study was to determine the prevalence of Adverse Drug Reactions in patients treated with chemotherapy.Methods: After getting approval from the Institutional Ethical Committee, the prospective observational study was conducted in the Department of Pharmacology in association with Department of Radiation Oncology and Department of Medicine, Government Medical College, Srinagar between April 2015 to October 2016. All patients of either sex and any age receiving anti-cancer drugs in the inpatient department of radiation oncology were included. The mean age of the study population was 51 years and 53.9% of them were males and 46.1% of them were females. The WHO-UMC system was used for assessment of case programme and case reports. The severity of adverse drug reactions was determined by using modified Hart wig and Siegel scale.Results: Most of the reported ADR’s were moderate to mild in severity according to modified Hart wig and Siegel scale. Most of the frequent ADR’s were certain followed by probable and possible according to WHO-UMC causality assessment.Conclusions: Antineoplastic drugs have a narrow therapeutic index and the dosage needed to achieve a therapeutic response usually proves toxic to the body’s rapidly proliferating cells. Measures need to be put into place to reduce the physical, emotional and economic burden on the patient due to adverse drug reactions. Therefore, there is a need for vigilant ADR monitoring to decrease morbidity and mortality due to ADR’s which require further studies on large populations.

Psychogenic Mass Syndrome in Anti-Cancer Drug Exposure

2010 ◽  
Author(s):  
N. Magnavita ◽  
I. lavicoli ◽  
V. Leso ◽  
A. Bergamaschi
Keyword(s):  
Drug Exposure ◽  
Cancer Drug ◽  
Anti Cancer

A Case of Malignant Melanoma Treated with a Combination of Anti-Cancer Drugs and Biological Response Modifiers.

1993 ◽  
Vol 55 (1) ◽  
pp. 43-46
Author(s):  
Jun YOSHIDA ◽  
Juichiro NAKAYAMA ◽  
Nobuyuki SHIMIZU ◽  
Shonosuke NAGAE ◽  
Yoshiaki HORI
Keyword(s):  
Malignant Melanoma ◽  
Biological Response ◽  
Biological Response Modifiers ◽  
Cancer Drugs ◽  
Anti Cancer

Current Scenario in Structure and Ligand-Based Drug Design on Anti-colon Cancer Drugs

2019 ◽  
Vol 24 (32) ◽  
pp. 3829-3841 ◽  
Author(s):  
Lakshmanan Loganathan ◽  
Karthikeyan Muthusamy
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
Anticancer Agent ◽  
Computational Power ◽  
Cancer Drugs ◽  
Recent Advances ◽  
Anti Cancer ◽  
Drug Designing ◽  
Current Scenario ◽  
Molecular Modeling Studies

Worldwide, colorectal cancer takes up the third position in commonly detected cancer and fourth in cancer mortality. Recent progress in molecular modeling studies has led to significant success in drug discovery using structure and ligand-based methods. This study highlights aspects of the anticancer drug design. The structure and ligand-based drug design are discussed to investigate the molecular and quantum mechanics in anti-cancer drugs. Recent advances in anticancer agent identification driven by structural and molecular insights are presented. As a result, the recent advances in the field and the current scenario in drug designing of cancer drugs are discussed. This review provides information on how cancer drugs were formulated and identified using computational power by the drug discovery society.

Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance

2020 ◽  
Vol 20 (9) ◽  
pp. 779-787
Author(s):  
Kajal Ghosal ◽  
Christian Agatemor ◽  
Richard I. Han ◽  
Amy T. Ku ◽  
Sabu Thomas ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Dna Repair ◽  
Fanconi Anemia ◽  
Cancer Drug ◽  
Drug Resistant ◽  
Cancer Drugs ◽  
Repair Pathway ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Cancerous Cells

Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one common obstacle to the success is the development of chemoresistance, which leads to failure of the previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.

Sign in / Sign up

Export Citation Format

Share Document